Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Sebnem YucelMehmet Ali Nahit SendurSebnem YucelEmir CelikDeniz Tataroglu OzyukselerMurat AyhanTugba BasogluAysegul IlhanNadiye AkdenizAhmet GulmezIzzet DoganBurak Yasin AktasMustafa GurbuzSinan KocaSemra PaydasAli Murat TatliHavva Yesil CinkirOzkan AlanCihan ErolMutlu HizalEngin KutSerkan MenevseTeoman SakalarHalil TaskaynatanGulhan Ipek DenizMustafa KaraagacOkan AvciErdem SenFatih KaratasMuhammed Bulent AkinciDidem Sener DedeAtakan DemirAhmet DemirkazıkBerna OksuzogluSadettin KilickapFulden YumukBulent YalcinPublished in: Journal of cancer research and clinical oncology (2021)
In our real-world study, afatinib has superior survival outcomes despite worse toxicity profile as inconsistent with clinical study results and it is the good upfront treatment option for younger patients and elderly patients who have good performance status.